Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Colorectal Neoplasms 53Colonic Neoplasms 11Neoplasms 10Rectal Neoplasms 9Neoplasm Metastasis 9Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 4Ovarian Neoplasms 4Lung Neoplasms 4Gastrointestinal Neoplasms 4Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Unresectable Metastatic Colorectal Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Ras-mutated Metastatic Colorectal Cancer 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroendocrine Tumors 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

azaspirane 2atezolizumab 2Everolimus 2Cisplatin 2tocilizumab 1repotrectinib 1pralsetinib 1pembrolizumab 1pasireotide 1durvalumab 1budigalimab 1Paclitaxel 1Nivolumab 1Leucovorin 1Irinotecan 1Ipilimumab 1IFL protocol 1Fluorouracil 1Etoposide 1EC regimen 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Neuroendocrine × IFL protocol × Clear all
NCT07595913 2026-05-19

A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Not yet recruiting
240 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡